Name: Theodora “Doretta” Mistras
New title: CFO, Edwards Lifesciences
Previous title: CFO, Viatris
Edwards Lifesciences has chosen Theodora “Doretta” Mistras as its next CFO.
Mistras’ appointment is effective at the end of May, the company said on Monday. She replaces Scott Ullem, whose decision to step down from the job after about 12 years was announced in October. Ullem will continue as a strategic adviser to Edwards.
Mistras has been CFO at pharmaceutical firm Viatris since March 2024, overseeing financial planning, reporting and operational finance for the global organization.
Before joining Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets and held senior leadership positions in healthcare investment banking at Goldman Sachs. Her experience includes helping guide boards and executive teams on corporate finance, strategy and investor relations.
Mistras’ time as CFO of a large public healthcare company and her familiarity with the investing side should make her a good fit for the new role, said BTIG analyst Marie Thibault. In April, Edwards raised its 2026 sales growth outlook, buoyed by strength in its transcatheter aortic replacement valve business in the first quarter. “Given the planned nature of this CFO transition, we are not expecting major changes to [Edwards’] financial outlook,” Thibault wrote in a research note.
Citi Research analyst Joanne Wuensch expected the appointment to be welcomed on Wall Street, writing that the announcement should be viewed positively by investors “now that the overhang on the CFO position has been addressed.”
